NASDAQ$WBA

Walgreens Boots Alliance Inc · Q1 2025 earnings

Q1 2025 earnings · · Investor relations

Briefing

Walgreens reported Q1 2025 results, showing sales increase but a loss per share, with adjusted EPS impacted by lower U.S. retail sales and prior year gains, offset by cost savings and U.S. Healthcare growth; maintained full year adjusted EPS guidance.

Walgreens Boots Alliance reported a 7.5% increase in sales to $39.5 billion for the first quarter of fiscal year 2025. However, the company experienced a loss per share of $0.31, although adjusted EPS was $0.51. The company is maintaining its fiscal year 2025 adjusted EPS guidance of $1.40 to $1.80.

  • First quarter sales increased 7.5% year-over-year to $39.5 billion.
  • Loss per share was $0.31, including costs related to the Footprint Optimization Program.
  • Adjusted EPS was $0.51, driven by lower U.S. retail sales and prior year sale-leaseback gains, partly offset by cost savings and growth in U.S. Healthcare.
  • Fiscal 2025 adjusted EPS guidance maintained at $1.40 to $1.80.

Headline financials

Total Revenue

$39.5B

Previous: $36.7B+7.5%
EPS (adj)

$0.51

Previous: $0.66-22.7%
Capital Expenditures

-$284M

Previous: -$506M+43.9%
Net Income

-$265M

Previous: -$67M-295.5%
Operating Income

-$245M

Previous: -$39M-528.2%
Gross Profit

$6.78B

Previous: $6.77B+0.1%
Stock-Based Comp

$38M

Previous: $51M-25.5%

Revenue & EPS history

Walgreens · Revenue · Quarterly

$39.5B

Q1 2025+7.5%vs Q1 2024
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Walgreens · $7.76B total across 2 segments · Q4 2023

  • International
    $5.78B
  • U.S. Healthcare
    $1.97B+217.0%

Forward guidance

Walgreens is maintaining its fiscal year 2025 adjusted EPS guidance of $1.40 to $1.80.

Tailwinds

  • Growth in U.S. Healthcare
  • Growth in International
  • Disciplined execution against 2025 priorities
  • Optimizing footprint
  • Controlling operating costs

Headwinds

  • Decline in U.S. Retail Pharmacy
  • Higher adjusted effective tax rate
  • Lower contributions from sale-leaseback
  • Lower Cencora earnings
  • Turnaround will take time

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 16 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.1%

Avg return

Earnings day

+0.4%

Avg return

5 days after

-1.9%

Avg return

30 days after

53%

33 / 62 earnings

Positive

+29.1%

Q1 2025

Best reaction

-22.7%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q3 2025+0.4%+1.5%+2.7%
Q2 2025-1.1%+0.5%+4.1%
Q1 2025+29.1%+36.1%+10.0%
Q4 2024+23.0%+18.7%-2.0%
Q3 2024-22.7%-26.0%-24.5%
Q2 2024-7.0%-10.9%-15.7%
Q1 2024-2.2%-0.6%-11.4%
Q4 2023+2.9%+2.1%-7.3%
Q3 2023-7.9%-10.2%-3.0%
Q2 2023+3.7%+5.0%+6.6%
Q1 2023-2.3%-2.1%-1.1%
Q4 2022+4.1%+3.8%+29.4%
Q3 2022-5.7%-5.7%-2.9%
Q2 2022-7.6%-8.4%-10.6%
Q1 2022-0.3%+0.6%-10.0%
Q4 2021+3.5%+1.5%+4.8%
Q3 2021-8.4%
Q2 2021+3.3%
Q1 2021+5.1%
Q4 2020+4.2%
Q3 2020-5.1%
Q2 2020-5.4%
Q1 2020-7.8%
Q4 2019+1.5%
Q3 2019+4.4%
Q2 2019-13.6%
Q1 2019-8.2%
Q4 2018+1.6%
Q3 2018-9.4%
Q2 2018-0.7%
Q1 2018-3.4%
Q4 2017-0.3%
Q3 2017+1.6%
Q2 2017-1.0%
Q1 2017+0.1%
Q4 2016+5.7%
Q3 2016-3.6%
Q2 2016-3.0%
Q1 2016+1.8%
Q4 2015-11.9%
Q3 2015+8.4%
Q1 2014+4.9%
Q2 2015+4.9%
Q4 2013+4.9%
Q1 2015+3.2%
Q4 2014-0.9%
Q3 2014+0.6%
Q2 2014+1.0%
Q3 2013-1.0%
Q2 2013+0.4%
Q1 2013+1.6%
Q4 2012+1.4%
Q3 2012-3.2%
Q2 2012-1.9%
Q1 2012+4.1%
Q4 2011+0.4%
Q3 2011-0.9%
Q2 2011+1.8%
Q1 2010+2.5%
Q4 2010+1.8%
Q3 2010-0.1%
Q2 2009+0.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro